SmartCella is a global biotech company pioneering the future of targeted therapies through delivery solutions and advanced therapy development. Founded in 2014, the company is built on globally renowned science and research from Karolinska Institutet in Sweden.
SmartCella combines novel delivery platforms, such as the Extroducer® (an endovascular delivery device that enables direct injection to hard-to-reach organs and tumors), with state-of-the-art development and manufacturing of stem cell-based therapies. The company operates in two business segments: Targeted Delivery and Regenerative Medicines.
The international team consists of scientists, visionary innovators, and experienced business leaders, all dedicated to shaping the future of targeted therapies and delivering life-changing treatments to patients.
Company Details
- Employees
- 64
- Founded
- -
- Address
- Alfred Nobels Alle 150, Tullinge,stockholm 14648,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- procella.se
- HQ
- Tullinge, Stockholm
Smartcella Holding Ab Questions
Smartcella Holding Ab's website is procella.se
Smartcella Holding Ab's LinkedIn profile is https://se.linkedin.com/company/smartcella
Smartcella Holding Ab has
64 employees.
View email and phone details for 64
employees at Smartcella Holding Ab.
Smartcella Holding Ab's industry is
Biotechnology Research
Smartcella Holding Ab's top competitors are
Pelago Bioscience Ab,
Northx Biologics,
Atmp Sweden,
Anocca,
Atlas Antibodies,
Biolamina,
Xbrane Biopharma Ab,
Nextcell Pharma Ab,
Cellcolabs,
Bioarctic.
Smartcella Holding Ab's categories are Biotechnology Research
Smartcella Holding Ab's founding year is 2014
